Adjuvant, adoptive immunotherapy with tumor infiltrating lymphocytes plus interleukin-2 after radical hepatic resection for colorectal liver metastases: 5-Year analysis

Journal of Surgical Oncology

Volumn 87, Issue 1, 2004, Pages 46-52

  Gardini, Andrea ^a   Ercolani, Giorgio ^a   Riccobon, Angela ^b   Ravaioli, Matteo ^a   Ridolfi, Laura ^b   Flamini, Emanuela ^b   Ridolfi, Ruggero ^b   Grazi, Gian Luca ^a   Cavallari, Antonino ^a   Amadori, Dino ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Pierantoni Hospital   (Italy)

Author keywords

Adoptive immunotherapy; Colorectal cancer; Liver metastases; TIL

Indexed keywords

ANTINEOPLASTIC AGENT; FAS ANTIGEN; FAS LIGAND; FLUOROURACIL; INTERLEUKIN 2; PROTEIN P56; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR EPSILON CHAIN; T LYMPHOCYTE RECEPTOR ZETA CHAIN; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; HYPERPYREXIA; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IMMUNOSTIMULATION; KIDNEY DYSFUNCTION; LIVER METASTASIS; LIVER RESECTION; LIVER TOXICITY; NEPHROTOXICITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEIZURE; TACHYCARDIA; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR IMMUNITY;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; COLORECTAL NEOPLASMS; FEMALE; HEPATECTOMY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; LIVER NEOPLASMS; LYMPHOCYTE SPECIFIC PROTEIN TYROSINE KINASE P56(LCK); LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, ANTIGEN, T-CELL;

EID: 3042771504     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.20066     Document Type: Article

References (38)

1. Ercolani G, Grazi GL, Ravaioli M, et al.: Liver resection for multiple colorectal metastases: Influence of parenchymal involvement and total tumor volume vs number or location, on long term survival. Arch Surg 2002;137:1187-1192.
2. Ohlsson B, Stenram U, Tranberg KG: Resection of colorectal liver metastases: 25-year experience. World J Surg 1998;22:268-277.
3. Chang A, Schneider PD, Sugarbaker PH, et al.: A prospective trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987;206:685-693.
4. Ballantyne GH, Quin J: Surgical treatment of liver metastases in patients with colorectal cancer. Cancer 1993;71(Suppl 12):4252-4266.
5. Vose BM, Moore M: Human tumour infiltrating lymphocytes: A marker of host response. Semin Hematol 1985;22:27-40.
6. Topalian SL, Muul LM, Solomon D, et al.: Expansion of human tumour infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods 1987;102:127-132.
7. Whiteside TL: Tumour infiltrating lymphocytes as antitumour effector cells. Biotherapy 1992;5:47-61.
8. Whiteside TL, Parmiani G. Tumour infiltrating lymphocytes: Their phenotype, function and clinical use. Cancer Immunol Immunother 1994;39:15-21.
9. Cole DJ, Taubemberger JK, Pockay BA, et al.: Histopathological analysis of metastatic melanoma deposits in patients receiving adoptive immunotherapy with tumour infiltrating lymphocytes. Cancer Immunol Immunother 1994;38:299-305.
10. Schwartzentruber DJ, Hom SS, Dadmarz R, et al.: In vitro predictors of therapeutic response in melanoma patients receiving tumour-infiltrating lymphocytes and Interleukin-2. J Clin Oncol 1994;12:1475-1483.
11. Pockaj BA, Sherry RM, Wei JP, et al.: Localization of III-Indium-labeled tumour infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer 1994;73:1731-1737.
12. Whiteside TL: Signaling defects in T lymphocytes of patients with malignancies. Cancer Immunol Immunother 1999;48:352-356.
13. Nakagomi H, Petersson M, Magnusson I, et al.: Decreased expression of the signal-transducing ζ chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res 1993;53:5610-5612.
14. Zier K, Gansbacher B, Salvadori S: Preventing abnormalities in signal transduction of T cells in cancer: The promise of cytokine gene therapy. Immmunology Today 1996;1:39-45.
15. Gansbacher BC: Clinical application of immunostimulatory gene transfer. Eur J Cancer 1994;30:1187-1194.
16. Guarini A, Riera L, Cignetti A, et al.: Transfer of the Interleukin-2 gene into human cancer cells induces specific antitumor recognition and restores the expression of CD3/T-cell receptor associated signal transduction molecules. Blood 1997;89:212-218.
17. West WH, Tauer KW, Yannelli JR, et al.: Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Eng J Med 1987;316:898-906.
18. Malafosse R, Penna C, Cunha A, et al.: Surgical management of hepatic metastases from colorectal malignancies. Arch Surg 1997;132:505-511.
19. Fujita K, Ikarashi H, Takakuwa K, et al.: Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumour infiltrating lymphocytes. Clin Cancer Res 1995;1:501-507.
20. De Paola F, Ridolfi R, Riccobon A, et al.: Restored T-cell activation mechanisms in human infiltrating lymphocytes from melanomas and colorectal carcinomas after exposure to interleukin-2. Br J Cancer 2003;88:320-326.
21. Palmer PA, Vinke J, Philip T, et al.: Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol 1992;3:475-480.
22. Takayama T, Sekine T, Makuuchi M, et al.: Adoptive immunotherapy to lower post surgical recurrence rates of hepatocellular carcinoma: A randomised trial. Lancet 2000;356:802-807.
23. Ridolfi L, Ridolfi R, Riccobon A, et al.: Adjuvant immunotherapy with tumor infiltrating lymphocytes and Interleukin-2 in patients with resected stage III and IV melanoma. J Immunother 2003;26:156-162.
24. Lai P, Rabinowich H, Crowley-Nowick PA, et al.: Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. Clin Cancer Res 1996;2:161-173.
25. Griffith TS, Brunner T, Fletcher SM, et al.: Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995;270:1189-1193.
26. Niehans GA, Brunner T, Frizelle SP, et al.: Human lung carcinomas express Fas ligand. Cancer Res 1997;57:1007-1012.
27. Pitti RM, Marsters SA, Lawrence DA, et al.: Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998;396:699-703.
28. Restifo NP, Rosenberg SA: Developing recombinant and synthetic vaccines for the treatment of melanoma. Curr Opin Oncol 1999;11:50-57.
29. Rivoltini L, Radrizzani M, Accomero P, et al.: Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing. J Immunol 1998;161:1220-1230.
30. Chappell DB, Zaks TZ, Rosenberg SA, et al.: Human melanoma cells do not express Fas (Apo-1/CD95) ligand. Cancer Res 1999;59:59-62.
31. Whiteside TL, Rabinowich H: The role of Fas/FasL in immunosuppression induced by human tumors. Cancer Immunol Immunother 1998;46:175-184.
32. Dillman RO, Oldham RK, Barth NM, et al.: Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trial. Cancer 1991;68:1-8.
33. Rosenberg SA, Yannelli JR, Yang JC, et al.: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994;86:1159-1166.
34. Goedegebuure PS, Douville LM, Li H, et al.: Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: A pilot study. J Clin Oncol 1995;13:1939-1949.
35. Figlin R, Mulders P, Gitlitz B, et al.: Cellular therapy of renal carcinoma past, present, future. Eur J Cancer 1997;33(Suppl 5):28-34.
36. Xu X, Xu L, Ding S, et al.: Treatment of 23 patients with advanced gastric cancer by intravenous transfer of autologous tumor-infiltrating lymphocytes combined with rIL-2. Chin Med Sci J 1995;10:185-187.
37. Freedman RS, Edwards CL, Kavanagh JJ, et al.: Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: A pilot trial. J Immunother Emphasis Tumor Immunol 1994;16:198-210.
38. Ratto GB, Zino P, Mirabelli S, et al.: A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected non small cell lung carcinoma. Cancer 1996;78:244-251.